stem cell therapy for calcific aortic valve disease(iPierian/Gladstone Institute of Cardiovascular Disease)

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug Namestem cell therapy for calcific aortic valve disease(iPierian/Gladstone Institute of Cardiovascular Disease)
Drug Alias NameiPS cell program (iPierian/Gladstone Institute of Cardiovascular Disease)induced pluripotent stem cell program (iPierian/Gladstone Institute of Cardiovascular Disease)
ClassificationCell and gene therapy > Cell therapy > Stem cell therapy
Mechanisms of ActionStem cells modulators
TargetsUpdating
Therapy Area/IndicationsAortic valve diseasesCardiovascular Diseases
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesIpierian Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesIpierian IncThe Gladstone Institute of Cardiovascular Disease
Active IndicationsN/A
Inactive IndicationsAortic valve diseasesCardiovascular Diseases

Other Information

ATC CodeN/A
Related LinksN/A